Table 2. Point prevalence of depressive symptoms by depression questionnaire(s).

	Point Prevalence % (n / total)	95% CI
≥ Mild depressive symptoms
PHQ-9 Positive (PHQ-9 ≥5)	55.1% (537 / 975)	51.89–58.23
BDI-II Positive (BDI-II ≥14)	27.7% (269 / 971)	24.91–30.63
BDI-II ≥14 or PHQ-9 ≥5	55.4% (556 / 1004)	52.24–58.48
≥ Moderate depressive symptoms
PHQ-9 Positive (PHQ-9 ≥10)	20.9% (204 / 975)	18.41–23.61
BDI-II Positive (BDI-II ≥20)	12.0% (117 / 971)	10.07–14.26
BDI-II ≥20 or PHQ-9 ≥10	22.8% (229 / 1004)	20.25–25.53

^a Number (%) of patients with non-missing data

Considering all patients with a BDI-II ≥14 or a PHQ-9 ≥5, the point prevalence of at least mild depressive symptoms based on one or the other questionnaire was 55.4% (95% CI: 52.24–58.48) (556 / 1004 patients; see Table 2). Using more restrictive cut-points indicating at least moderate depressive symptoms, i.e. BDI-II ≥20 or PHQ-9 ≥10, the point prevalence was 22.8% (95% CI 20.25–25.53) (229 / 1004 patients) (Table 2).

Patients with at least mild depressive symptoms were less likely to have ACR/EULAR Boolean remission than patients with no depressive symptoms (16.3% vs 37.2%), and other chronic pain was more frequently reported by these patients than patients with no depressive symptoms (13.1% vs 4.7%).